A Phase 2 interventional study of 60 mg AIC246 and 120 mg AIC246 in HCMV Reactivation or HCMV End-Organ Disease, sponsored by AiCuris Anti-infective Cures AG. Completed at 24 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-13.
Sponsored by AiCuris Anti-infective Cures AG · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of the study is to find out whether AIC246 is safe and efficacious in lowering the chances of the cytomegalovirus becoming active again and causing illness after an HBPC transplant (allogeneic stem cell transplant).
AiCuris Anti-infective Cures AG is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
60 mg AIC246, one tablet per day
Drug: 60 mg AIC246
120 mg AIC246, one tablet per day
Drug: 120 mg AIC246
240 mg AIC246, one tablet per day
Drug: 240 mg AIC246
Placebo arm
Other: Placebo
Oral administration
Oral administration
Oral administration
Oral administration
Number of Participants With "HCMV Prophylaxis Failure"
Time frame: 84 days
Time to Onset of "HCMV Prophylaxis Failure"
Time frame: 84 days
Number of Patients With Systemic Detectable HCMV Replication.
Time frame: 84 days
| Milestone | AIC246 (60 mg) | AIC246 (120 mg) | AIC246 (240 mg) | Placebo |
|---|---|---|---|---|
| Started | 33 | 31 | 34 | 33 |
| Completed | 17 | 21 | 24 | 12 |
| Not completed | 16 | 10 | 10 | 21 |
| Participants | AIC246 (60 mg) | AIC246 (120 mg) | AIC246 (240 mg) | Placebo |
|---|---|---|---|---|
| Number of Participants With "HCMV Prophylaxis Failure" | 16 | 10 | 10 | 21 |
| days | AIC246 (60 mg) | AIC246 (120 mg) | AIC246 (240 mg) | Placebo |
|---|---|---|---|---|
| Time to Onset of "HCMV Prophylaxis Failure" | 7 | 6 | 2 | 12 |
| Participants | AIC246 (60 mg) | AIC246 (120 mg) | AIC246 (240 mg) | Placebo |
|---|---|---|---|---|
| Number of Patients With Systemic Detectable HCMV Replication. | 7 | 5 | 2 | 12 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AIC246 (60 mg) | 2/33 (6.1%) | 13/33 (39.4%) | 31/33 (93.9%) |
| AIC246 (120 mg) | 1/31 (3.2%) | 15/31 (48.4%) | 29/31 (93.5%) |
| AIC246 (240 mg) | 1/34 (2.9%) | 12/34 (35.3%) | 34/34 (100%) |
| Placebo | 1/33 (3%) | 16/33 (48.5%) | 33/33 (100%) |
| Event | AIC246 (60 mg) | AIC246 (120 mg) | AIC246 (240 mg) | Placebo |
|---|---|---|---|---|
| Acute Graft Versus Host Disease in IntestineImmune system disorders | 4/33 | 0/31 | 2/34 | 2/33 |
| PyrexiaGeneral disorders | 1/33 | 0/31 | 0/34 | 3/33 |
| PneumoniaInfections and infestations | 2/33 | 2/31 | 2/34 | 0/33 |
| Acute Myeloid LeukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/33 | 2/31 | 0/34 | 0/33 |
| Cytomegalovirus InfectionInfections and infestations | 0/33 | 1/31 | 0/34 | 2/33 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 0/33 | 1/31 | 0/34 | 2/33 |
| Spinal Compression FractureInjury, poisoning and procedural complications | 2/33 | 0/31 | 0/34 | 0/33 |
| Transplant FailureInjury, poisoning and procedural complications | 2/33 | 0/31 | 0/34 | 0/33 |
| LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/33 | 0/31 | 2/34 | 0/33 |
| Enterococcal BacteraemiaInfections and infestations | 0/33 | 1/31 | 0/34 | 0/33 |
| Event | AIC246 (60 mg) | AIC246 (120 mg) | AIC246 (240 mg) | Placebo |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 7/33 | 8/31 | 7/34 | 11/33 |
| Cytomegalovirus InfectionInfections and infestations | 6/33 | 6/31 | 5/34 | 11/33 |
| DiarrhoeaGastrointestinal disorders | 9/33 | 9/31 | 11/34 | 10/33 |
| VomittingGastrointestinal disorders | 4/33 | 10/31 | 8/34 | 4/33 |
| FatigueGeneral disorders | 3/33 | 8/31 | 4/34 | 5/33 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/33 | 8/31 | 5/34 | 1/33 |
| Oedema PeripheralGeneral disorders | 4/33 | 3/31 | 8/34 | 3/33 |
| HeadacheNervous system disorders | 4/33 | 3/31 | 8/34 | 3/33 |
| RashSkin and subcutaneous tissue disorders | 4/33 | 5/31 | 4/34 | 6/33 |
| PyrexiaGeneral disorders | 3/33 | 4/31 | 5/34 | 6/33 |
| Age, Continuous(years) | AIC246 (60 mg) | AIC246 (120 mg) | AIC246 (240 mg) | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 50.5 ± 13.03 | 51.6 ± 12.79 | 50.7 ± 11.78 | 51.8 ± 13.41 | 51.1 ± 12.62 |
| Sex: Female, Male(Participants) | AIC246 (60 mg) | AIC246 (120 mg) | AIC246 (240 mg) | Placebo | Total |
|---|---|---|---|---|---|
| Female | 19 | 9 | 12 | 14 | 54 |
| Male | 14 | 22 | 22 | 19 | 77 |
| Region of Enrollment(participants) | AIC246 (60 mg) | AIC246 (120 mg) | AIC246 (240 mg) | Placebo | Total |
|---|---|---|---|---|---|
| United States | 18 | 19 | 17 | 15 | 69 |
| Germany | 15 | 12 | 17 | 18 | 62 |
The record gives a start of Mar 2010, a primary completion of Oct 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2018, 6 years 4 months after primary completion. A results delay was requested in Jan 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Letermovir
AiCuris Anti-infective Cures AG